MedTrace Logo

Genetic Information to Inform Treatment and Screening for Prostate Cancer, GIFTS Study

NCT04254133 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 1360

Last updated 2026-01-30

No results posted yet for this study

Summary

This trial studies the role of inherited (present at birth) mutations in cancer risk genes such as BRCA2, BRCA1, ATM, CHEK2, and others in relation to prostate cancer. This study may help researchers understand the frequency and importance of inherited mutations in cancer risk genes in patients with prostate cancer and potentially help identify better ways to treat cancer in patients who have a mutation in one of these genes.

Conditions

  • Prostate Carcinoma

Interventions

BEHAVIORAL

Questionnaire

Complete questionnaire

PROCEDURE

Biospecimen Collection

Provide saliva samples

DIAGNOSTIC_TEST

Genetic Testing

Undergo genetic testing

OTHER

Genetic Counseling

Undergo counseling

OTHER

Laboratory Biomarker Analysis

Correlative Studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Fred Hutchinson Cancer Center

    lead OTHER

Principal Investigators

  • Burcu Darst · Fred Hutch/University of Washington Cancer Consortium

  • Heather H Cheng · Fred Hutch/University of Washington Cancer Consortium

  • Daniel W Lin · Fred Hutch/University of Washington Cancer Consortium

  • Colin C Pritchard · Fred Hutch/University of Washington Cancer Consortium

Eligibility

Min Age
35 Years
Max Age
89 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-30
Primary Completion
2028-08-31
Completion
2028-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04254133 on ClinicalTrials.gov